Posted by Michael Wonder on 10 Jan 2020
Meissa Vaccines receives U.S. FDA fast track designation for respiratory syncytial virus vaccine, MV-012-968
10 January 2020 - Meissa Vaccines announced today that the U.S. FDA has granted fast track designation to MV-012-968, an investigational, live attenuated vaccine for protection against respiratory syncytial virus infection.
The FDA’s fast track program expedites the development and review of drugs and biologic agents demonstrating potential to fill an unmet medical need in the treatment or prevention of serious conditions.
A Phase 1 clinical trial evaluating the safety and immunogenicity of MV-012-968 is presently recruiting healthy adult volunteers.
